ÂÜÀòÂÒÂ×

Angela J. Russell, DPhil was elected to the Scientific Advisory Board in September 2020.

Professor Russell’s research interests are centered around the discovery of new molecules and mechanisms to manipulate cell fate and to translate them into therapeutic agents, particularly for degenerative diseases. She has initiated a number of collaborative research programmes, including a medicinal chemistry approach to the modulation of gene expression to treat fatal rare genetic diseases such as Duchenne muscular dystrophy (DMD). She has published over 100 original articles, book chapters and patent applications. She co-founded the Oxford spin-out MuOx Ltd, (now part of Summit Therapeutics plc), and co-founded OxStem Ltd in 2016. In 2016 she was named as a ‘Rising Star’ in the UK BioBeat 50 Movers and Shakers in BioBusiness report, which celebrates 50 outstanding women entrepreneurs and business leaders who are recognised for their contributions to global health innovation. In October 2020 she was awarded a 2021 Harrington UK Rare Disease scholarship in recognition of, and in support of, her work on developing a therapy for DMD.

Professor Russell gained her MChem degree from the University of Oxford in 2000 and her DPhil in Organic Chemistry in 2004. In 2007 she was awarded a prestigious Research Councils’ UK Fellowship in Medicinal Chemistry jointly between the Departments of Chemistry and Pharmacology in Oxford. In 2018 she was conferred to Professor of Medicinal Chemistry.